Chemistry:4'-Methyl-α-pyrrolidinopropiophenone
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C14H19NO |
| Molar mass | 217.312 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
4'-Methyl-α-pyrrolidinopropiophenone (4-MePPP, MPPP or MαPPP) is a stimulant drug and substituted cathinone. It is structurally very similar to α-PPP, with only one added methyl group in the para position on the phenyl ring. 4-MePPP was sold in Germany as a designer drug in the late 1990s and early 2000s,[2][3][4] along with a number of other pyrrolidinophenone derivatives.[5][6] Although it has never achieved the same international popularity as its better-known relations α-PPP and MDPV, 4-MePPP is still sometimes found as an ingredient of grey-market "bath salt" blends[7] such as "NRG-3".[7]
Legality
In the United States 4-MePPP is considered a schedule 1 controlled substance as an positional isomer of alpha-pyrrolidinopentiophenone (α-PVP)[8]
See also
- α-Pyrrolidinopropiophenone (α-PPP)
- 4'-Methoxy-α-pyrrolidinopropiophenone (MOPPP)
- 3,4-Methylenedioxy-α-pyrrolidinopropiophenone (MDPPP)
- 3',4'-Methylenedioxy-α-pyrrolidinobutiophenone (MDPBP)
References
- ↑ "Cannabinoider föreslås bli klassade som hälsofarlig vara" (in sv). Folkhälsomyndigheten. http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/.
- ↑ "Studies on the metabolism and toxicological detection of the new designer drug 4'-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 773 (1): 25–33. June 2002. doi:10.1016/S1570-0232(01)00578-5. PMID 12015267.
- ↑ "Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes". Drug Metabolism and Disposition 31 (8): 979–982. August 2003. doi:10.1124/dmd.31.8.979. PMID 12867484.
- ↑ "Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 796 (2): 253–266. November 2003. doi:10.1016/j.jchromb.2003.07.008. PMID 14581066.
- ↑ "Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis". Therapeutic Drug Monitoring 26 (2): 127–131. April 2004. doi:10.1097/00007691-200404000-00007. PMID 15228152.
- ↑ "Metabolism of designer drugs of abuse". Current Drug Metabolism 6 (3): 259–274. June 2005. doi:10.2174/1389200054021825. PMID 15975043.
- ↑ 7.0 7.1 "Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones". Drug Testing and Analysis 3 (9): 569–575. September 2011. doi:10.1002/dta.204. PMID 21960541.
- ↑ "Lists of: Scheduling Actions Controlled Substances Regulated Chemicals". U.S. Department of Justice. February 2023. https://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf.
 |  |
